Artivion, Inc. (NYSE:AORT) CEO James P. Mackin Sells 42,156 Shares

Artivion, Inc. (NYSE:AORT) CEO James P. Mackin sold 42,156 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the sale, the chief executive officer now owns 663,882 shares of the company’s stock, valued at approximately $18,130,617.42. This trade represents a 5.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Artivion Trading Down 0.5 %

AORT opened at $25.44 on Thursday. The company has a fifty day moving average price of $29.68 and a two-hundred day moving average price of $27.83. Artivion, Inc. has a 1-year low of $18.38 and a 1-year high of $32.33. The company has a market cap of $1.07 billion, a P/E ratio of -1,272.00 and a beta of 1.75. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT) last issued its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. Analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on AORT. Needham & Company LLC cut their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. Stifel Nicolaus dropped their price objective on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 target price on shares of Artivion in a research note on Tuesday, December 10th. Finally, Oppenheimer lifted their target price on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $31.40.

Institutional Investors Weigh In On Artivion

Hedge funds and other institutional investors have recently modified their holdings of the company. Quarry LP grew its position in Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after purchasing an additional 820 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after buying an additional 786 shares during the last quarter. R Squared Ltd bought a new stake in shares of Artivion during the fourth quarter worth about $39,000. Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion in the 4th quarter worth about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Artivion in the 4th quarter valued at about $64,000. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.